Propanc Biopharma (NASDAQ:PPCB – Get Free Report) and Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.
Profitability
This table compares Propanc Biopharma and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Propanc Biopharma | N/A | -151.28% | -109.53% |
| Ionis Pharmaceuticals | -64.76% | -111.08% | -17.41% |
Valuation and Earnings
This table compares Propanc Biopharma and Ionis Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Propanc Biopharma | N/A | N/A | -$58.92 million | ($24.25) | -0.05 |
| Ionis Pharmaceuticals | $944.00 million | 10.63 | -$381.39 million | ($3.46) | -17.46 |
Propanc Biopharma has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Propanc Biopharma has a beta of 3.52, meaning that its share price is 252% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
Insider & Institutional Ownership
93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 28.7% of Propanc Biopharma shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings for Propanc Biopharma and Ionis Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Propanc Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Ionis Pharmaceuticals | 1 | 4 | 17 | 0 | 2.73 |
Ionis Pharmaceuticals has a consensus target price of $94.15, suggesting a potential upside of 55.88%. Given Ionis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Propanc Biopharma.
Summary
Ionis Pharmaceuticals beats Propanc Biopharma on 8 of the 13 factors compared between the two stocks.
About Propanc Biopharma
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
